Bristol Myers will enroll more patients in its Cobenfy Alzheimer's psychosis study after site irregularities, with FDA-supported analysis suggesting encouraging early signals.
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction ...
The FDA has granted accelerated approval to Otsuka’s Voyxact for adults with primary IgAN at risk of disease progression, ...
Semaglutide medications like Ozempic and Wegovy can help lower the risk of heart and metabolic diseases in people with ...
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...
Study data suggests IGV-001 provides patients with a clinically meaningful improvement in overall survival (+6.3 months; +45%) compared to the current standard of care for ndGBM –– Company plans to ...
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac ...
Results from the GLISTEN study, the largest investigational trial of pruritus in primary biliary cholangitis (PBC), indicate ...
At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that ...
The novel B cell-targeting therapy ianalumab demonstrated improvement over placebo in key Sjögren’s disease parameters, ...
AbbVie (NYSE: ABBV) today announced primary results from the pivotal Phase 3 ECLIPSE study, evaluating the safety, efficacy and tolerability of atogepant (60 mg) versus placebo for the acute treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback